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ABSTRACT
Objective An umbrella review summarising all safety data 
from systematic reviews of topical corticosteroids (TCS) in 
adults and children with atopic eczema.
Methods Embase, MEDLINE, PubMed, Cochrane Database 
of Systematic Reviews and the Centre of Evidence Based 
Dermatology map of eczema systematic reviews were 
searched until 7 November 2018 and Epistemonikos until 
2 March 2021. Reviews were included if they assessed the 
safety of TCS in atopic eczema and searched >1 database 
using a reproducible search strategy. Review quality was 
assessed using version 2 of 'A MeaSurement Tool to 
Assess systematic Reviews' (AMSTAR 2 tool).
Results 38 systematic reviews included, 34 low/critically 
low quality. Treatment and follow- up were usually short 
(2–4 weeks).
Key findings TCS versus emollient/vehicle: No meta- 
analyses identified for skin- thinning. Two 2- week 
randomised controlled trials (RCTs) found no significant 
increased risk with very potent TCS (0/196 TCS vs 0/33 
vehicle in children and 6/109 TCS vs 2/50 vehicle, age 
unknown). Biochemical adrenal suppression (cortisol) was 
3.8% (95% CI 2.4% to 5.8%) in a meta- analysis of 11 
uncontrolled observational studies (any potency TCS, 522 
children). Effects reversed when treatment ceased.
TCS versus topical calcineurin inhibitors: Meta- analysis 
showed higher relative risk of skin thinning with TCS (4.86, 
95% CI 1.06 to 22.28, n=4128, four RCTs, including one 
5- year RCT). Eight cases in 2068 participants, 7 using 
potent TCS. No evidence of growth suppression.
Once daily versus more frequent TCS: No meta- analyses 
identified. No skin- thinning in one RCT (3 weeks potent 
TCS, n=94) or biochemical adrenal suppression in two 
RCTs (up to 2 weeks very potent/moderate TCS, n=129).
TCS twice/week to prevent flares (‘weekend therapy’) 
versus vehicle: No meta- analyses identified. No evidence 
of skin thinning in five RCTs. One RCT found biochemical 
adrenal suppression (2/44 children, potent TCS).
Conclusions We found no evidence of harm when TCS were 
used intermittently ‘as required’ to treat flares or ‘weekend 
therapy’ to prevent flares. However, long- term safety data 
were limited.
PROSPERO registration number CRD42018079409.
INTRODUCTION
Atopic eczema (also known as atopic derma-
titis or eczema) is an itchy inflammatory skin 
condition. It is most common in children 
with one in five affected worldwide,1 2 but 
often persists into adulthood.3
Topical corticosteroids (TCSs) are first- line 
therapy for treating inflammatory eczema 
flares but widespread concerns regarding 
their safety among patients and healthcare 
professionals contribute to poor adherence, 
and subsequent worsening of disease control 
and quality of life.4 5 Safety concerns include 
skin thinning and retardation of growth and 
development. These concerns are thought to 
mainly originate from what is now considered 
to be inappropriate use, such as using potent 
TCS on the face or continual long- term use.6 
Strategies recommended to minimise expo-
sure to TCS, and hence the risk of adverse 
events, include reducing frequency of appli-
cation to once daily during treatment of an 
inflammatory episode, or TCS used for two 
consecutive days a week (sometimes referred 
to as ‘weekend therapy’) as a strategy to 
prevent flares.7–9 This umbrella review aims 
Strengths and limitations of this study
 ► Robust Cochrane methodology was followed and 
a thorough and inclusive literature search was 
performed to ensure this was a comprehensive 
overview.
 ► By extracting data from existing reviews, results are 
limited to topics for which there is an eligible sys-
tematic review.
 ► Safety was usually reported in less detail than effec-
tiveness in systematic reviews limiting the available 
data for extraction, therefore potentially missing 
data included in the original papers.
 ► Most included reviews were rated low or critically 
low- quality using AMSTAR 2, and where quality of 
evidence assessments were reported for individual 
studies most indicated a high or unclear risk in at 
least one domain.
 ► Many randomised controlled trials were only short 
in duration (2–4 weeks) limiting our ability to assess 
side effects that take longer to develop such as skin 
thinning.
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to assess safety (local and systemic adverse events) of TCS 
compared with other topical treatments, placebo or no 
comparator in people of any age and gender with atopic 
eczema, and addressed two areas of research prioritised 
in the James Lind Alliance priority setting partnership for 
atopic eczema.10
METHODS
Protocol, registration and study design
This umbrella review includes published systematic 
reviews of randomised controlled trials (RCTs) and/
or observational studies reporting adverse event data in 
people with eczema using TCS. The aim of this overview 
was to summarise data from existing reviews, therefore, 
meta- analyses and data from individual studies were 
extracted and presented in this overview in the format 
and completeness that they were presented in the original 
systematic reviews. The only exception was for missing 
p values which were calculated where appropriate. The 
checklist ‘Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA)’ was followed.11 12
Search strategy
Embase, MEDLINE, PubMed, Cochrane Database of 
Systematic Reviews and Epistemonikos were searched 
from inception to 7 November 2018 by DJCG (informa-
tion specialist), with no restrictions on language or publi-
cation date. The search strategy is in online supplemental 
appendix 1. The Epistemonikos search was updated on 2 
March 2021, with a publication date restricted to 2018–
2021. Epistemonikos is now well established as a compre-
hensive database of reviews that regularly searches ten 
major databases including the Cochrane Library, PubMed 
and Embase13 thus making the need to search these indi-
vidual databases redundant. We also checked the Centre 
of Evidence Based Dermatology eczema map of system-
atic reviews,14 and searched PROSPERO up to 23 March 
2021 for any relevant ongoing systematic reviews using 
the terms ‘eczema’ and ‘dermatitis’.
Eligibility criteria
We included systematic reviews that presented data on the 
safety of TCS used to treat people of any age and gender 
with atopic eczema, had clinical outcomes, searched at 
least one database and provided a reproducible search 
strategy. Systematic reviews of any types of clinical study 
design were included. Multiple reviews on the same topic 
were included, except for ‘abridged’ versions of the same 
review where no additional data were reported. To avoid 
duplication of data, for each comparison, the review that 
included the highest number of studies on that compar-
ison and therefore appeared the most comprehensive was 
taken as the primary review and other included reviews 
were checked for additional studies and data. Conference 
abstracts were excluded. Reviews that covered multiple 
skin conditions were only included if they reported data 
on atopic eczema patients separately.
Interventions and control
Our intervention of interest was any TCS of any prepa-
ration and potency used to treat atopic eczema. For 
RCTs, the comparisons of interest were any other TCS, 
the same TCS used in a different way, another topical 
anti- inflammatory treatment, vehicle, no treatment or 
a combination of any of these. Comparisons with non- 
topical treatments were excluded as we were interested in 
clinical practice decisions regarding alternatives to TCS.
Outcomes
Safety outcomes reported during the treatment and 
follow- up were extracted where reported in the reviews 
on immediate cutaneous adverse events (eg, burning 
sensation/stinging), other cutaneous adverse events (eg, 
skin thinning, telangiectasia, skin infections, folliculitis), 
systemic adverse events (eg, effects on endocrine system, 
impact on growth) and rebound symptoms/steroid 
withdrawal.
Selection of studies and data extraction
Records identified from the database searches were 
uploaded into Covidence (Veritas Health Innovation, 
Australia).15 Two authors (EA and JRC) independently 
assessed the eligibility of each record, and where unclear 
the full text was obtained. The number of included and 
excluded records along with reasons for exclusion were 
reported in a PRISMA flow diagram.
Two authors (EA and JRC) independently extracted all 
safety data presented in the included reviews along with 
other information such as review/participant character-
istics, and funding sources. Any disagreements regarding 
eligibility or data extraction were resolved via discussion 
or input from a third reviewer (HCW or KST). Where 
available, we reported results separately for age, filaggrin 
mutation status, TCS potency, site of application of the 
TCS, and duration of continuous treatment.
Assessment of quality of included systematic reviews
As this was an overview of reviews, the methodological 
quality of the evidence was assessed at the systematic 
review level using version 2 of 'A MeaSurement Tool to 
Assess systematic Reviews' (AMSTAR 2 tool) and this was 
conducted in duplicate by EA and JRC.16 Reviews were 
considered critically low quality if there was more than 
one critical flaw. Data on the quality of individual studies 
(eg, risk of bias) and the quality of evidence (eg, Grading 
of Recommendations Assessment, Development and Eval-
uation, GRADE17) were also extracted where presented 
in the review, but undertaking these quality assessments 
for individual studies was not within the remit of this 
overview.
Measures of treatment effect and data synthesis
Where relevant meta- analyses were presented in the 
systematic review, the forest plots, relative risk (RR) 
and 95% CI were extracted. In the absence of any meta- 
analysis, adverse event data from individual studies were 
included in this overview based on the data presented in 
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the published systematic review. P values were calculated 
using Review Manager software,18 with <0.05 indicating 
statistically significant results. Where meta- analyses were 
presented, we assessed the following subgroups where 
possible: age, TCS potency, anatomical site, treatment 
duration and genetic predisposition to a disrupted skin 
barrier (filaggrin status). TCS potency was determined 
using a hierarchy of sources: UK ‘British National Formu-
lary’, WHO and USA classifications.19–21 A National 
Health Service classification ranging from very common 
(>1 in 10 people affected) to very rare (<1 in 10 000) 
was used to narratively describe the absolute risk of each 
adverse event.22
Patient and public involvement
People with eczema and parents of children with eczema 
were involved in the decision to conduct this overview and 
in the design. The James Lind Alliance priority setting 
partnership for atopic eczema involved people with 
eczema and parents of children with eczema in which 
two of the identified priority areas were around research 
into the safety of TCS.10 Two of the overview authors are 
patient representatives (AR and AA) and both have been 
involved in the design of this overview and interpretation 
of the findings.
Wider patient and parent involvement has been partic-
ularly important in identifying important safety outcomes 
for this overview. We held a workshop involving five 
patient representatives in which the proposed overview 
was discussed which highlighted the need to seek out data 
on long- term TCS use, reversibility of any side effects and 
TCS withdrawal symptoms. We supplemented this with 
a survey about safety concerns with TCS at a National 
Eczema Society meeting of 31 people with eczema or 
parents of children with eczema and a published qualita-
tive study of patient concerns relating to TCS safety.6
Dissemination of the results is underway as part of the 
wider programme of research of which this overview is a 




After deduplication, 635 records were screened; 127 
records underwent full- text screening and 38 systematic 
reviews met the inclusion criteria (figure 1).7 8 23–56 The list 
of excluded reviews is in online supplemental appendix 2. 
The search of PROSPERO identified five ongoing system-
atic reviews (online supplemental appendix 3).57–61
Characteristics and quality of the included systematic reviews
All but three reviews were published in English. Two 
Chinese reviews and one German review were translated 
into English.32 36 45 Thirty of the included reviews were 
rated critically low quality according to AMSTAR 2; with 
four low, two moderate and two high quality (table 1). 
The most common reasons for downgrading were no 
protocol, no list of full- text exclusions or a literature 
search restricted to the English language.
The included reviews identified 106 studies (77 RCTs 
and 29 observational studies) that included relevant safety 
data. Risk of bias assessments were available from the 
reviews for 63 RCTs, of which 42 used the Cochrane risk 
of bias tool. Most of these assessments rated at least one 
domain as high or unclear risk, most noticeably selection 
bias from lack of allocation concealment, performance 
bias due to lack of blinding of participants and detec-
tion bias due to lack of blinding of outcome assessors. 
The trials included in the reviews usually evaluated use 
of short bursts of TCS (2–4 weeks) to treat the flare but 
varied greatly in length of follow- up. Around two- thirds 
of trials included no post- treatment follow- up, while the 
remainder included several weeks/months of follow- up 
generally using TCS intermittently ‘as required’. A total of 
14 RCTs (5874 participants) and 5 cohort/observational 
Figure 1 PRISMA flow diagram. PRISMA, Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses.
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Table 1 Characteristics of included systematic reviews
First author, 
publication year Type of review
Review contained safety data 
from RCTs for comparisons of 
interest?
Review contained 
safety data from 
observational studies? AMSTAR 2 rating
Ashcroft 200524 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6 7
Ashcroft 200723 Cochrane Yes (TCS vs TCI) Yes (TCS vs TCI) Moderate8
Barnes 201525 Non- Cochrane Yes (TCS vs vehicle, TCS vs TCI,
TCS vs another TCS)
Yes (single arm TCS 
studies)
Critically low 1 2 3 4 6
Braham 201026 Non- Cochrane Yes (occluded TCS vs non- 
occluded TCS)
Yes (occluded TCS) Critically low 1 2 3 4 6
Broeders 201627 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 5 6
Callen 200728 Non- Cochrane Yes (TCS vs vehicle, TCS vs 
another TCS)
Yes (single arm studies 
or comparing TCS 
potencies)
Critically low 1 2 3 4 6
Chen 201029 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6
Cury Martins 201530 Cochrane Yes (TCS vs TCI) Yes (TCS vs TCI) Moderate8
De Tiedra 199731 Non- Cochrane Yes (TCS vs another TCS) Yes (usually only 
reported data from one 
arm of RCTs)
Critically low 1 2 3 4 6
Devillers 200632 Non- Cochrane Yes (occluded TCS vs non- 
occluded TCS)
Yes (occluded TCS) Critically low 1 2 3 4 6
Dong 201733 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 2 3 4 6
Eichenfield 201434 Non- Cochrane No Yes (different TCS 
potencies)
Critically low 1 2 3 4 6
Feldman 200535 Non- Cochrane Yes (TCS vs vehicle) No Critically low 1 2 3 4 6
Fishbein 201963 Non- Cochrane Yes (TCS vs vehicle/moisturiser) No Critically low 3 4 5 6 7
Frangos 200836 Non- Cochrane Yes (TCS vs vehicle) Yes (single arm studies) Critically low 1 2 3 4 6
Froeschl 200737 GMS HTA report Yes (TCS vs vehicle, TCS vs TCI,
TCS vs another TCS)
No Critically low 1 2 4 6
Gonzalez- Lopez 
201738
Non- Cochrane Yes (occluded TCS vs non- 
occluded TCS)
No Critically low 1 3
Green 20047 HTA report Yes (once daily vs twice daily TCS 
use)
No Low
Gu 201340 Cochrane Yes (TCS vs topical CHM) No High
Gu 201439 Non- Cochrane Yes (TCS vs topical CHM) No Critically low 1 2 3 7
Hajar 201541 Non- Cochrane No Yes (case series or case 
reports)
Critically low 2 3 6
Hoare 200042 NIHR HTA report Yes (TCS vs vehicle, TCS vs 
another TCS)
No Low
Iskedjian 200443 Non- Cochrane Yes (TCS vs vehicle, TCS vs TCI) No Critically low 1 3 6
Juhász 201744 Non- Cochrane No Yes (social media 
analysis)
Critically low 1 2 3 4 6
Abędź 201982 Non- Cochrane Yes (TCS vs TCI) No Critically low1 3 6 7
Legendre 201545 Non- Cochrane No Yes (TCS vs TCI) Critically low 1 2 3 6
Li 200746 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6
Nankervis 201647 NIHR HTA report Yes (TCS vs vehicle, TCS vs 
emollients, TCS vs TCI, TCS 
vs another TCS, once a day vs 
twice a day use, proactive TCS to 
prevent flares (‘weekend therapy’) 
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studies (4 438 698 participants) out of a total of 106 
studies included follow- up of more than 3 months. One 
notable trial (the ‘PETITE’ study) had 5 years follow- up 
with TCS used ‘as required’.62
Characteristics and quality assessments of each system-
atic review are in table 1, with further detail in online 
supplemental appendices 4 and 5. Individual study data 
and quality assessments are in online supplemental 
appendix 6.
Safety of TCS compared with other topical treatments or 
corticosteroids
How safe are TCS compared with emollient or vehicle, or no 
comparison?
Thirteen reviews provided data on this comparison: 1 
high54, 2 low42 47 and 10 critically low quality.25 28 31 35–37 50 51 55 63 
Key results can be found in table 2 and additional data in 
online supplemental appendix 6.
Reported rates of skin thinning in RCTs were gener-
ally very low, with no significant increases seen with TCS 
compared with emollient/vehicle. No skin thinning or 
telangiectasia was reported in an RCT, 196 participants 
aged ≥12 years old using very potent TCS twice a day 
for 2 weeks compared with 33 using vehicle.64 Another 
RCT reported skin thinning in 6/109 participants using 
very potent TCS for 2 weeks compared with 2/50 using 
vehicle, p=0.69.65
No significant differences in other cutaneous adverse 
events, such as hypopigmentation, were observed between 
treatments in five RCTs, and event rates were low.66–70
A meta- analysis55 of 11 uncontrolled observational 
studies (up to 4 weeks of treatment) reported biochem-
ical adrenal suppression (cortisol levels) in 20/522 chil-
dren (3.8%, 95% CI 2.4% to 5.8%) with any potency 
TCS.71–81 This was 2% (3/148 children) when only mild 
potency TCS were analysed.72 74 77 79 No clinical symptoms 
or signs of adrenal suppression were observed,71–81 and 
the biochemical effects were transient, with cortisol levels 
returning to normal after TCS were discontinued.71 75 77 78 81
Two included reviews assessed TCS withdrawal symp-
toms, mostly from case reports, but no incidence data 
were reported.41 44
How safe are TCS compared with topical calcineurin inhibitors?
Eight systematic reviews were identified: one moderate23, 
one low48 and six critically low quality.27 30 43 50 52 82 Most 
RCTs used twice daily TCS to treat the current flare (up to 
3 weeks), and where longer- term follow- up was included, 
TCSs were used ‘as required’ to treat flares. Key results 
First author, 
publication year Type of review
Review contained safety data 
from RCTs for comparisons of 
interest?
Review contained 
safety data from 
observational studies? AMSTAR 2 rating
Burls 200448 West Midlands HTA 
report
Yes (TCS vs TCI) No Low
Schmitt 20118 Non- Cochrane Yes (proactive TCS to prevent 
flares (‘weekend therapy’) vs 
vehicle)
No Critically low 3 6
Sidbury 201449 Non- Cochrane Yes (proactive TCS to prevent 
flares (’weekend therapy’) vs 
vehicle)
No Critically low 1 2 3 4 6
Siegfried 201650 Non- Cochrane Yes (TCS vs vehicle, TCS vs TCI,
TCS vs another TCS)
No Critically low 1 2 3 4 6
Singh 201251 Non- Cochrane Yes (TCS vs vehicle, TCS vs TCI,
TCS vs another TCS)
Yes (single arm study) Critically low 1 2 6
Svensson 201152 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6 7
Tang 201453 Non- Cochrane Yes (proactive TCS to prevent 
flares (‘weekend therapy’) vs 
vehicle)
No Critically low 1 3 4 6
van Zuuren 201754 Cochrane Yes (TCS vs emollient) No High
Wood Heickman 
201855
Non- Cochrane No Yes (single arm cohort 
studies)
Critically low 1 2 3 4 6 7
Yan 200856 Non- Cochrane Yes (TCS vs TCI) No Critically low 1 3 6 7
AMSTAR 2 ratings—reasons for downgrading the quality of the review: 1No protocol; 2Search strategy not comprehensive; 3No list of 
excluded studies with reasons; 4Risk of bias not assessed; 5Inappropriate meta- analysis methods; 6Risk of bias assessments not included in 
the interpretation of the results; 7Publication bias not explored in the meta- analysis.
Additional data on TCS including potency can be found in online supplemental appendix 6.
CHM, Chinese herbal medicine; GMS, German Medical Science; HTA, Health Technology Assessment; NIHR, National Institute for Health 
Research; RCTs, randomised controlled trials; TCI, topical calcineurin inhibitors; TCS, topical corticosteroid.
Table 1 Continued
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Table 2 Summary of main findings for key safety outcomes
Cutaneous adverse events Systemic adverse events
How safe are TCS compared 





10 critically low quality
 ► Skin thinning: No significant differences in 2 
RCTs of 2–4 weeks compared with emollient/
vehicle: (1) 0/196 children with very potent 
TCS and 0/33 vehicle, (2) 6/109 very potent 
TCS vs 2/50 vehicle, p=0.69. Very low rates.
 ► Other cutaneous adverse events: No 
significant differences in 5 RCTs (2–4 weeks) 
between TCS (various potencies) and 
emollient/vehicle (n=172, plus one study, n 
not specified). Low event rates.
 ► Biochemical evidence of adrenal 
suppression: Meta- analysis (11 
observational studies, max 4 
weeks)—20/522 children with any 
potency TCS (3.8%, 95% CI 2.4% to 
5.8%), 3/148 children (2%) with mild 
potency TCS. Effects were transient.
 ► Clinical symptoms or signs of 
adrenal suppression: none observed 
in same as above observational 
studies.
How safe are TCS compared 





6 critically low quality
 ► Skin thinning: Higher with TCS than TCI 
(meta- analysis of 4 RCTs: RR 4.86, 95% 1.06 
to 22.28, n=4128) but very low rate (8/2068, 
7 of which were using potent TCS).
 ► Other cutaneous adverse events: No 
difference in skin infections between TCS 
and TCI (8 RCTs). Skin burning and pruritus 
lower with TCS than TCI: meta- analysis of 
10 RCTs: burning—RR 0.31, 95% CI 0.23 to 
0.40 (n=4211), pruritus—RR 0.68, 95% CI 
0.56 to 0.82(n=4211).
 ► Growth rate: no differences in growth 
rates tween TCS and TCI (1 RCT of 
2418 children with 5 years follow- up).
 ► Lymphoma: no cases reported in one 
same large RCT as above. One cohort 
study (n=1 438 333, approx. 4 years 
follow- up)—very small non- significant 
increase with TCI and TCS compared 
with general population. One case–
control study—no increased risk with 
TCS or TCIs (294 cases/293 000 
controls).
How safe are once daily TCS 




 ► Skin thinning: no cases using once daily vs 
twice daily potent TCS for 3 weeks (1 RCT, 
94 adults).
 ► Other cutaneous adverse events: no 
significant difference between groups in 
telangiectasia, folliculitis, or burning/
itching/stinging (4 RCTs, 4–16 weeks 
follow- up 740 older children/adults).
 ► Biochemical evidence of adrenal 
suppression: no significant differences 
between once and twice daily 
moderate/potent TCS up to 2 weeks in 
children (2 RCTs, n=129).
How safe are TCS used 
proactively to prevent flares 
(‘weekend therapy’)?
3 reviews:
3 critically low quality
 ► Skin thinning: no cases with 16–20 weeks 
of 2 days/week of potent TCS vs vehicle (5 
RCTs, n=993).
 ► Other cutaneous adverse events: no 
significant differences between groups, 
including folliculitis and transient 
telangiectasia, with potent TCS (16–20 
weeks) compared with either vehicle or 
another TCS (2 RCTs, n=423). Events were 
uncommon in both groups.
 ► Biochemical evidence of adrenal 
suppression: no cases with 16 weeks 
of 2 days/week of potent TCS (2 RCTs, 
n=129). Possible adrenal suppression 
in 2/44 children with potent TCS 
compared with zero using vehicle (1 
RCT, 20 weeks).




3 critically low quality
 ► Skin thinning: no cases in two observational 
studies (potent TCS +wet wrap, 1–2 weeks, 
n=44).
 ► Other cutaneous adverse events: One 
case of striae in two observational studies, 
n-44. More folliculitis with diluted potent 
TCS (10/19 children) compared with 
emollient (2/20), both under wet wrap (1 
RCT). A meta- analysis (2 RCTs, n=69) of wet 
wrap vs no wet wrap (mild potency)—no 
significant difference in cutaneous adverse 
events.
 ► Biochemical evidence of adrenal 
suppression: reported in three 
observational studies (2–14 days of 
diluted potent TCS under wet- wraps in 
74 children) but rates not specified in 
review. Described as transient in two 
studies.
 ► Growth or bone turnover: no 
effect seen in one small short- term 
observational study (potent TCS wet- 
wrap in eight children, (median follow- 
up 12 weeks).
RCTs, randomised controlled trials; RR, relative risk; TCS, topical corticosteroids.
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can be found in table 2 and additional data in online 
supplemental appendix 6.
Meta- analyses of cutaneous adverse events were 
presented in two reviews.27 82 So the more comprehen-
sive review was used to extract the cutaneous adverse 
event data.27 Some minor modifications were made to 
the data for this overview shown in online supplemental 
appendix 7. A meta- analysis of four RCTs (26 weeks to 
5 years duration, twice a day or ‘as directed’) showed a 
significant increase in the RR of skin thinning with TCS 
compared with topical calcineurin inhibitors (TCIs) 
(0.1% tacrolimus or 1% pimecrolimus) (RR 4.86, 95% CI 
1.06 to 22.28, p=0.04, n=4128). However, skin thinning 
was uncommon: 8/2068 participants (0.4%) with TCS vs 
0/2060 (0%) with TCIs. Of the eight cases of skin thin-
ning, seven were reported when using potent TCS and 
one using mild/moderate TCS.62 83–85
The RR of skin burning and pruritus (itching) was 
significantly lower with TCS compared with TCIs (1% 
pimecrolimus or 0.1 % / 0.03% tacrolimus) in meta- 
analyses of 10 RCTs in 4211 participants (skin burning: RR 
0.31, 95% CI 0.23 to 0.40, p<0.00001; pruritus: RR 0.68, 
95% CI 0.56 to 0.82, p<0.0001).83 85–93 The GRADE assess-
ments for these two adverse events indicated these were 
of moderate quality.82 There was no significant difference 
in skin infections with potent, moderate or mild potency 
TCS compared with TCIs (1% pimecrolimus or 0.1 
%/0.03% tacrolimus)62 83–86 88 90 92 or erythema compared 
with 0.1% tacrolimus (online supplemental appendix 
8).91 92
Subgroup analyses of age, TCS potency and specific 
TCI showed no significant differences for any compar-
ison (online supplemental appendix 9). We were unable 
to undertake any further subgroup analyses.
No differences in growth were observed in one 5- year 
RCT (‘PETITE’ study) in 2418 young children using 
moderate/mild potency TCS compared with those using 
TCI (1% pimecrolimus) (rates not given) and no cases 
of lymphoma were reported.62 A large cohort study (n=1 
438 333) showed a small non- significant increased risk of 
lymphoma with TCI and TCS compared with the general 
population, with a similar risk between treatments.94 In 
addition, one case–control study (294 cases/293 000 
controls) found no increased risk of lymphoma with TCS 
or TCI compared with controls.95
Is there any difference in safety of TCS of different potencies?
Six reviews compared the safety of different potency TCS: 
two low,42 47 and four critically low quality.28 34 50 53 RCTs 
were mainly short- term use of TCS (2–3 weeks), used 
once or twice daily. Results can be found in online supple-
mental appendix 6.
One RCT reported mild skin thinning in 4/13 chil-
dren using potent TCS for up to 6 weeks compared 
with 2/12 using mild TCS (p=0.42),96 while another 
RCT in 37 children found no evidence of skin thinning 
with mild or moderate potency TCS for 3 weeks.97 One 
study compared 3 weeks of potent and moderate TCS in 
40 children and reported ‘some’ biochemical adrenal 
suppression (cortisol levels) but no numerical data were 
provided.98
How safe are TCS compared with topically applied Chinese herbal 
medicine?
Two systematic reviews provided data on TCS compared 
with topical Chinese herbal medicine: one high quality40 
and one critically low.39 Results can be found in online 
supplemental appendix 6.
A meta- analysis of two RCTs99 100 was presented in two 
systematic reviews.39 40 More cutaneous adverse events, 
including application site burning, were observed with 2 
weeks of very potent/potent TCS compared with topical 
Chinese herbal medicine (RR 12.03, 95% CI 1.59 to 
91.26, p=0.02; 11/147 vs 0/148 participants). One addi-
tional RCT, including 95 young children, reported minor 
adverse events such as burning with 2 weeks of potent 
TCS but no numerical data were presented.101
Safety of different strategies for using TCS
How safe are once daily TCS compared with more frequent 
application?
Two low- quality reviews provided safety data relating to 
different frequency of application.7 47 Key results can be 
found in table 2 and additional data in online supple-
mental appendix 6.
No skin thinning was reported with once or twice 
daily application of potent TCS for 3 weeks in one RCT 
(94 adults).102 Four RCTs in 740 older children/adults 
showed no significant difference between once and twice 
daily application of moderate/potent TCS in other cuta-
neous adverse events including telangiectasia,103 104 follic-
ulitis105 and burning, itching or stinging.105 106 Two RCTs 
showed no significant differences in biochemical adrenal 
suppression (cortisol levels) between once and twice daily 
very potent/moderate TCS used for up to 2 weeks in 129 
children.81 107
How safe are TCS when used proactively to prevent flares 
(‘weekend therapy’)?
Two reviews included data on the safety of TCS used 
proactively 2 days a week (‘weekend therapy’) to prevent 
flares, both critically low quality.8 53 Key results can be 
found in table 2 and additional data in online supple-
mental appendix 6.
There was no evidence of skin thinning in five RCTs 
comparing 16–20 weeks of weekend therapy with potent 
TCS versus vehicle in 993 participants.103 108–111 Further-
more, two RCTs (n=423) reported no significant differ-
ences in other cutaneous adverse events, including 
folliculitis and transient telangiectasia, with potent TCS 
compared with vehicle.108 109 Events were uncommon in 
both groups.
There was no evidence of biochemical adrenal suppres-
sion (cortisol levels) in two RCTs (n=129) between potent 
TCS and vehicle used for 16 weeks.108 111 In a 20- week 
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RCT, 2/44 children had possible adrenal suppression 
with potent TCS compared with zero with vehicle.109
How safe are TCS used under occlusion?
Four reviews included data on the safety of TCS used 
under occlusion: one high54, and three critically low 
quality.26 32 38 Results can be found in online supplemental 
appendix 6.
There were no cases of skin thinning and one case 
of striae in two uncontrolled observational studies of a 
diluted potent TCS used under wet- wrap for 1–2 weeks 
in 44 young children.112 113 A significant difference in the 
rate of folliculitis (mostly mild) was observed in one RCT 
of TCS under wet- wrap for 4 weeks, with more follicu-
litis in the diluted potent TCS group (10/19 children) 
compared with emollient (2/20 children) (p=0.02).114 A 
meta- analysis from one review38 of two RCTs in young chil-
dren showed no significant difference in the number of 
participants with cutaneous adverse events between mild 
potency TCS under wet wrap (7/38 participants) versus 
not under wet- wrap (0/31 participants) (p=0.08)115 116; 
this evidence was rated low quality by the systematic review 
authors using GRADE.17
Biochemical adrenal suppression (cortisol levels) was 
reported in three uncontrolled observational studies of 
2–14 days of diluted potent TCS under wet- wraps in 74 
children.112 113 117 Actual rates were not specified in the 
review, but increases were described as transient in two 
studies.112 117 One short- term uncontrolled observational 
study of diluted potent TCS under wet- wrap in eight chil-
dren showed no effect on growth or bone turnover.118
DISCUSSION
This comprehensive overview of systematic reviews 
which, for the first time, brings together all safety data 
from systematic reviews on TCS used in eczema from 38 
systematic reviews, a topic that was identified as a priority 
in a James Lind Alliance priority setting partnership on 
eczema. Skin thinning and effects on growth concern 
many people with eczema and parents of children with 
eczema when using TCS. However, we found no evidence 
of skin thinning when TCS were used intermittently ‘as 
required’ to treat flares or as ‘weekend therapy’ to prevent 
flares, although the majority of data was from short- 
term studies.5 Similarly, we found no evidence of growth 
retardation or clinically significant adrenal suppression 
but the only data available was from one 5- year study 
that included 1213 children using TCS.62 Other studies 
only reported biochemical signs of adrenal suppression. 
Adherence to TCS treatment is known to be poor and 
these findings, particularly around skin thinning, may 
encourage appropriate use of TCS and therefore improve 
treatment effectiveness and patient benefit.119
A thorough literature search was conducted and 
Cochrane methodology was used. Conclusions were 
limited by the content of the included reviews because 
safety was frequently reported in less detail than 
effectiveness, reviews reported on different adverse 
events and some adverse events were not described in 
the reviews. It is not clear whether this is because the 
trials did not report adverse events in sufficient detail or 
whether the review authors did not include all the avail-
able safety data, perhaps only focusing on a restricted 
group of adverse events. None of the included systematic 
reviews presented data on our prespecified subgroup 
analyses. Furthermore, most of the included reviews were 
rated low or critically low- quality using AMSTAR 2. The 
lack of comprehensive search strategies and duplicate 
screening/data extraction in the included reviews may 
have resulted in missing studies and safety data, which 
could have impacted on this overview particularly where 
there was limited data. In addition, where the quality of 
evidence assessments (eg, GRADE) were reported in the 
reviews, most individual studies included in the reviews 
indicated a high or unclear risk in at least one domain.
Many RCTs did not include follow- up beyond 2–4 weeks 
of treatment and therefore data on long- term safety are 
limited. Although short- term TCS use reflects appropriate 
treatment duration for treating an individual flare, it does 
not reflect the chronic nature of eczema and the need 
for TCS use over the long- term. The ‘PETITE study’ was 
the notable exception and data published in the corre-
spondence showed there was only one episode of skin 
thinning in 1213 children using mild/moderate TCS ‘as 
required’ with 5- year follow- up.62 Trials using intermittent 
TCS as ‘weekend therapy’ to prevent flares also provide 
reassurance for the safety of longer- term use of TCS, as 
these trials generally included 16–20 weeks of follow- up 
to assess the prevention of flares. The inclusion of system-
atic reviews that included observational studies as well as 
reviews of RCTs also increased the amount of safety data 
available to report in this overview.
Although this review focused on the safety of TCS as the 
key issue for patients, treatment decisions are a balance 
of benefits and harms. For example, although the safety 
profile of Chinese herbal medicine was better than TCS, 
in practice this would be considered alongside the rela-
tive effectiveness of these treatments. Likewise, although 
there was no difference in the safety of once vs twice daily 
TCS, effectiveness of these regimens is also important to 
consider. A Cochrane review is underway comparing the 
effectiveness and safety of different ways of using TCS.120
In summary, we found no evidence that TCS cause 
harm when used intermittently ‘as required’ to treatment 
eczema flares or as ‘weekend therapy’ to prevent flares 
and this should support the use of TCS in the manage-
ment of eczema. We found that the adverse events of 
greatest concern to patients and clinicians, such as skin 
thinning, are uncommon with short- term use of TCS. 
However, high- quality evidence was limited, particularly 
for long- term use. Rather than follow- up of perhaps just a 
few weeks, future RCTs should include lengthier follow- up 
to enable better safety assessment. However, it should be 
noted that longer- term prospect observational studies are 
better placed to explore longer- term safety of TCS and 
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should be designed with years rather than months of 
follow- up to add useful information to the field. Perhaps 
equally as important as duration of follow- up in trials is 
resolution of adverse events which is often not reported. 
For adverse events such as biochemical signs of adrenal 
suppression, it is crucial to know if the effect is transient 
and levels return to normal once the TCS is stopped, 
particularly as it is not clear how to interpret the clinical 
relevance of these.
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